MA53015A - Anticorps anti-sirp-bêta1 et procédés d'utilisation associés - Google Patents
Anticorps anti-sirp-bêta1 et procédés d'utilisation associésInfo
- Publication number
- MA53015A MA53015A MA053015A MA53015A MA53015A MA 53015 A MA53015 A MA 53015A MA 053015 A MA053015 A MA 053015A MA 53015 A MA53015 A MA 53015A MA 53015 A MA53015 A MA 53015A
- Authority
- MA
- Morocco
- Prior art keywords
- sirp
- associated procedures
- beta1
- antibodies
- beta1 antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862691913P | 2018-06-29 | 2018-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53015A true MA53015A (fr) | 2021-05-05 |
Family
ID=67439371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053015A MA53015A (fr) | 2018-06-29 | 2019-06-28 | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210277113A1 (fr) |
EP (1) | EP3814377A2 (fr) |
JP (1) | JP2021529520A (fr) |
KR (1) | KR20210025614A (fr) |
CN (1) | CN112384532A (fr) |
AU (1) | AU2019293589A1 (fr) |
BR (1) | BR112020026819A2 (fr) |
CA (1) | CA3099176A1 (fr) |
EA (1) | EA202190138A1 (fr) |
IL (1) | IL279648A (fr) |
MA (1) | MA53015A (fr) |
MX (1) | MX2020013324A (fr) |
SG (1) | SG11202010990TA (fr) |
WO (1) | WO2020006374A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018000073A (es) | 2015-06-30 | 2018-06-27 | Sanford Burnham Med Res Inst | Agonistas de proteina de fusion btla y usos de los mismos. |
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
WO2021217024A1 (fr) * | 2020-04-24 | 2021-10-28 | Millennium Pharmaceuticals, Inc. | Anticorps anti-cd19 et leurs utilisations |
WO2022115350A1 (fr) * | 2020-11-30 | 2022-06-02 | Merck Sharp & Dohme Corp. | Liants d'arginase 1 pour inhiber l'activité de l'arginase 1 |
EP4255451A1 (fr) * | 2020-12-03 | 2023-10-11 | The Board Of Regents Of The University Of Texas System | Méthodes d'identification d'anticorps bloquant lilrb |
CN114478802B (zh) * | 2022-01-28 | 2023-05-26 | 郑州大学 | 一种嵌合抗原受体及其应用 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2481837A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
JP4224586B2 (ja) * | 2004-04-28 | 2009-02-18 | 国立大学法人群馬大学 | マクロファージ活性化剤並びにその製造方法及びスクリーニング方法 |
MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
EP4316465A3 (fr) | 2006-03-15 | 2024-04-24 | Alexion Pharmaceuticals, Inc. | Traitement de patients souffrant d'hémoglobinurie paroxystique nocturne par un inhibiteur du complément |
CA2651567A1 (fr) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Polypeptides de liaison a squelettes optimises |
EP2471816A1 (fr) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Anticorps multi-spécifiques |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
EP2193146B1 (fr) | 2007-09-14 | 2016-05-25 | Adimab, LLC | Bibliothèques d'anticorps synthétiques rationnelles et leurs utilisations |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
CN101880324B (zh) * | 2010-05-25 | 2012-10-17 | 中国人民解放军第二军医大学 | 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用 |
EP4219805A1 (fr) | 2010-07-16 | 2023-08-02 | Adimab, LLC | Banques d'anticorps |
CN103748114B (zh) | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T细胞活化性双特异性抗原结合分子 |
US20140242095A1 (en) | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
AU2013267161A1 (en) * | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
EP2991679A4 (fr) | 2013-04-29 | 2016-12-07 | Adimab Llc | Réactifs multispécificité, procédés de préparation et d'utilisation associés |
WO2015138600A2 (fr) * | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anticorps anti-sirp-alpha et anticorps bispécifiques de stimulation des macrophages |
GB201413357D0 (en) * | 2014-07-28 | 2014-09-10 | Philogen Spa | Antibodies for treatment and diagnosis |
CA2977257A1 (fr) * | 2015-02-22 | 2016-08-25 | Sorrento Therapeutics, Inc. | Agents therapeutiques de type anticorps se liant a cd137 |
CA2996059A1 (fr) * | 2015-08-28 | 2017-03-09 | Alector Llc | Anticorps anti-siglec-7 et leurs methodes d'utilisation |
JP2018535655A (ja) * | 2015-09-29 | 2018-12-06 | アムジエン・インコーポレーテツド | Asgr阻害剤 |
WO2018210793A2 (fr) * | 2017-05-16 | 2018-11-22 | Synthon Biopharmaceuticals B.V. | ANTICORPS ANTI-SIRPα |
-
2019
- 2019-06-28 CN CN201980040821.9A patent/CN112384532A/zh active Pending
- 2019-06-28 SG SG11202010990TA patent/SG11202010990TA/en unknown
- 2019-06-28 EP EP19744960.6A patent/EP3814377A2/fr active Pending
- 2019-06-28 WO PCT/US2019/039757 patent/WO2020006374A2/fr active Application Filing
- 2019-06-28 CA CA3099176A patent/CA3099176A1/fr active Pending
- 2019-06-28 JP JP2020572914A patent/JP2021529520A/ja active Pending
- 2019-06-28 BR BR112020026819-4A patent/BR112020026819A2/pt unknown
- 2019-06-28 EA EA202190138A patent/EA202190138A1/ru unknown
- 2019-06-28 MX MX2020013324A patent/MX2020013324A/es unknown
- 2019-06-28 KR KR1020217002521A patent/KR20210025614A/ko unknown
- 2019-06-28 AU AU2019293589A patent/AU2019293589A1/en active Pending
- 2019-06-28 US US17/256,508 patent/US20210277113A1/en active Pending
- 2019-06-28 MA MA053015A patent/MA53015A/fr unknown
-
2020
- 2020-12-21 IL IL279648A patent/IL279648A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019293589A1 (en) | 2021-01-21 |
US20210277113A1 (en) | 2021-09-09 |
WO2020006374A2 (fr) | 2020-01-02 |
CN112384532A (zh) | 2021-02-19 |
JP2021529520A (ja) | 2021-11-04 |
SG11202010990TA (en) | 2020-12-30 |
EP3814377A2 (fr) | 2021-05-05 |
BR112020026819A2 (pt) | 2021-04-20 |
MX2020013324A (es) | 2021-05-12 |
KR20210025614A (ko) | 2021-03-09 |
IL279648A (en) | 2021-03-01 |
CA3099176A1 (fr) | 2020-01-02 |
EA202190138A1 (ru) | 2021-05-27 |
WO2020006374A3 (fr) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA52781A (fr) | Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies | |
MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA46770A (fr) | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation | |
MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
MA47691A (fr) | Anticorps anti-cd33 et leurs procédés d'utilisation | |
MA52416A (fr) | Anticorps b7-h4 et leurs procédés d'utilisation | |
MA43658A (fr) | Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA52963A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation |